Literature DB >> 23753029

In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline.

Jason H Mendler, Kati Maharry, Heiko Becker, Ann-Kathrin Eisfeld, Leigha Senter, Krzysztof Mrózek, Jessica Kohlschmidt, Klaus H Metzeler, Sebastian Schwind, Susan P Whitman, Jihane Khalife, Michael A Caligiuri, Rebecca B Klisovic, Joseph O Moore, Thomas H Carter, Guido Marcucci, Clara D Bloomfield.   

Abstract

Entities:  

Keywords:  NPM1; RUNX1; acute myeloid leukemia; mutational interrelationships; mutations

Mesh：

Substances：

Year:  2013        PMID： 23753029      PMCID： PMC3729891          DOI： 10.3324/haematol.2013.089904

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  MutationTaster evaluates disease-causing potential of sequence alterations.

Authors:  Jana Marie Schwarz; Christian Rödelsperger; Markus Schuelke; Dominik Seelow
Journal:  Nat Methods       Date:  2010-08       Impact factor: 28.547

2.  P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808.

Authors:  Jonathan E Kolitz; Stephen L George; Guido Marcucci; Ravi Vij; Bayard L Powell; Steven L Allen; Daniel J DeAngelo; Thomas C Shea; Wendy Stock; Maria R Baer; Vera Hars; Kati Maharry; Eva Hoke; James W Vardiman; Clara D Bloomfield; Richard A Larson
Journal:  Blood       Date:  2010-06-03       Impact factor: 22.113

3.  RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes.

Authors:  Philipp A Greif; Nikola P Konstandin; Klaus H Metzeler; Tobias Herold; Zlatana Pasalic; Bianka Ksienzyk; Annika Dufour; Friederike Schneider; Stephanie Schneider; Purvi M Kakadia; Jan Braess; Maria Cristina Sauerland; Wolfgang E Berdel; Thomas Büchner; Bernhard J Woermann; Wolfgang Hiddemann; Karsten Spiekermann; Stefan K Bohlander
Journal:  Haematologica       Date:  2012-06-11       Impact factor: 9.941

4.  RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis.

Authors:  Susanne Schnittger; Frank Dicker; Wolfgang Kern; Nicole Wendland; Jana Sundermann; Tamara Alpermann; Claudia Haferlach; Torsten Haferlach
Journal:  Blood       Date:  2010-12-09       Impact factor: 22.113

5.  Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621.

Authors:  Jonathan E Kolitz; Stephen L George; Richard K Dodge; David D Hurd; Bayard L Powell; Steven L Allen; Enrique Velez-Garcia; Joseph O Moore; Thomas C Shea; Eva Hoke; Michael A Caligiuri; James W Vardiman; Clara D Bloomfield; Richard A Larson
Journal:  J Clin Oncol       Date:  2004-11-01       Impact factor: 44.544

6.  Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy.

Authors:  Carolyn J Owen; Cynthia L Toze; Anna Koochin; Donna L Forrest; Clayton A Smith; Jane M Stevens; Shannon C Jackson; Man-Chiu Poon; Gary D Sinclair; Brian Leber; Peter R E Johnson; Anthony Macheta; John A L Yin; Michael J Barnett; T Andrew Lister; Jude Fitzgibbon
Journal:  Blood       Date:  2008-08-21       Impact factor: 22.113

7.  AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations.

Authors:  Jih-Luh Tang; Hsin-An Hou; Chien-Yuan Chen; Chieh-Yu Liu; Wen-Chien Chou; Mei-Hsuan Tseng; Chi-Fei Huang; Fen-Yu Lee; Ming-Chih Liu; Ming Yao; Shang-Yi Huang; Bor-Sheng Ko; Szu-Chun Hsu; Shang-Ju Wu; Woei Tsay; Yao-Chang Chen; Liang-In Lin; Hwei-Fang Tien
Journal:  Blood       Date:  2009-10-06       Impact factor: 22.113

8.  Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B.

Authors:  R J Mayer; R B Davis; C A Schiffer; D T Berg; B L Powell; P Schulman; G A Omura; J O Moore; O R McIntyre; E Frei
Journal:  N Engl J Med       Date:  1994-10-06       Impact factor: 91.245

9.  RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.

Authors:  Verena I Gaidzik; Lars Bullinger; Richard F Schlenk; Andreas S Zimmermann; Jürgen Röck; Peter Paschka; Andrea Corbacioglu; Jürgen Krauter; Brigitte Schlegelberger; Arnold Ganser; Daniela Späth; Andrea Kündgen; Ingo G H Schmidt-Wolf; Katharina Götze; David Nachbaur; Michael Pfreundschuh; Heinz A Horst; Hartmut Döhner; Konstanze Döhner
Journal:  J Clin Oncol       Date:  2011-02-22       Impact factor: 50.717

10.  A knock-in Npm1 mutation in mice results in myeloproliferation and implies a perturbation in hematopoietic microenvironment.

Authors:  Shiu-Huey Chou; Bor-Sheng Ko; Ji-Shain Chiou; Yueh-Chwen Hsu; Mong-Hsun Tsai; Yu-Chiao Chiu; I-Shing Yu; Shu-Wha Lin; Hsin-An Hou; Yi-Yi Kuo; Hsiu-Mei Lin; Ming-Fang Wu; Wen-Chien Chou; Hwei-Fang Tien
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240
View more
  4 in total

1.  Reply to "rare coincident NPM1 and RUNX1 mutations in intermediate risk acute myeloid leukemia display similar patterns to single mutated cases". Haematologica 2014;99(2):e20-21.

Authors:  Jason H Mendler; Guido Marcucci; Clara D Bloomfield
Journal:  Haematologica       Date:  2014-02       Impact factor: 9.941

2.  Rare coincident NPM1 and RUNX1 mutations in intermediate risk acute myeloid leukemia display similar patterns to single mutated cases.

Authors:  Annette Fasan; Claudia Haferlach; Alexander Kohlmann; Frank Dicker; Christiane Eder; Wolfgang Kern; Torsten Haferlach; Susanne Schnittger
Journal:  Haematologica       Date:  2014-02       Impact factor: 9.941

3.  [RUNX1 gene mutations are associated with adverse prognosis of patients with acute myeloidleukemia].

Authors:  Yanli Yang; Tiantian Li; Yinghua Geng; Jun Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2020-11-30

4.  The landscape of gene co-expression modules correlating with prognostic genetic abnormalities in AML.

Authors:  Chao Guo; Ya-Yue Gao; Qian-Qian Ju; Chun-Xia Zhang; Ming Gong; Zhen-Ling Li
Journal:  J Transl Med       Date:  2021-05-29       Impact factor: 5.531
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.